Method of prevention of early sepsis in children tyazheloobozhzhennykh

 

(57) Abstract:

The invention relates to medicine, in particular to combustology, and can be used for prevention of early sepsis in tyazheloobozhzhennykh children. The method is carried out by holding in the period of burn shock and acute toxemia of traditional therapy and the introduction in the first five days of human recombinant interferon - reaferona, and on the sixth day of the inductor of interferon - cycloferon in the age dosages within the muscle. The method leads to increased anti-infective organism protection through targeted activation of interferon. table 1.

The present invention relates to medicine, in particular to combustology, and can be used for prevention of early sepsis in tyazheloobozhzhennykh children.

The known method of prevention of early sepsis in tyazheloobozhzhennykh children by including in the medical complex antistaphylococcal gamma globulin and specific plasma (see Zhegalov A. A. Treatment of burn shock in critical and supercritical thermal burns in children // Burn disease.: Proc.Dokl. - Kiev, 1988. - S. 49).

However, this method is unidirectional and predlagaga sepsis, consisting in infusion therapy, the introduction of anticoagulants, antiplatelet, heart drugs, antibiotics, vitamins, immune drugs: thymalin, hyperimmune antidiagonal plasma and serum modern drugs (see Alekseev, A. A. Burn sepsis: diagnosis, prevention, and treatment: abstract. Prof. dis., Moscow, 1993, S. 18-23).

However, the known method can only work on certain parts of humoral immunity, primarily on the content of immunoglobulins in the blood. The method makes it possible to influence the interferon system, which is the most important factor of nonspecific resistance of the organism.

The task of the invention is the strengthening of the anti-infective organism protection through targeted activation of interferon.

The problem is solved due to the fact that in the method, including traditional therapy in the period of burn shock and acute toxemia, in the first five days after injury injected in the age dosage intramuscular injection of human recombinant interferon - IFN, and on the sixth day inducer of interferon - cycloferon in the next five days.

Postuplenii children with burns on the area more than 10% of body surface immediately begin to conduct antishock therapy, includes intravenous drip fluid infusion electrolyte, colloid and salt-free environments, as well as anticoagulants, antiplatelet, glucocorticoid drugs, vitamins, antioxidants, broad-spectrum antibiotics, etc. Also introduce the complex immunomodulatory drugs: during the first five days designated human recombinant interferon - IFN dose 30000 ME per 1 kg of body weight, and on the sixth day after burn cycloferon in a dose of 0.005 g per 1 kg of body weight over the next five days. IFN and cold intramuscularly.

Method of prevention of early sepsis in tyazheloobozhzhennykh children applied in the national burn center in 43 patients. Simultaneously analyzed group of patients, called the control, consisting of 48 children treated without the use of this method.

The analysis shows that the frequency of early sepsis in patients treated with the use of this method, was 2.2 times lower than that reflected in the table.

Clinical examples.

1. Sick samsin Daniil Vladimirovich, 11 years old, I. B. 182917 was hospitalized in the national burn centre based in Nizhny Novgorod research Institute of Traugot: electric shock, flame burn volt arc II-III AB - IV degree of the face, trunk, upper and lower extremities on the area of 70% of the body surface (including IIIB Art. - 35% of body surface). A very severe burn shock.

In the intensive care unit the children's burn units immediately started antishock therapy, including intravenous fluid infusion medium (glucose-saline solutions, reopoligliukina, HAES-steril, gemodeza), painkillers, sedatives, heart, antihistamines, glucocorticoid drugs. The patient was laid on a bed-net for the installation of infrared radiation.

On the background of resuscitation and antibiotic therapy (Fortum 1 g x 3 times intravenously) through day after injury initiated immune-corrective therapy: IFN at a dose of 500,000 IU twice daily intramuscularly for five days, then cold 2 ml intramuscularly in the next five days.

The patient was removed from a state of extremely severe burn shock. Clinical and laboratory methods study early signs of sepsis in the period of burn shock and toxemia have been identified. Positive dynamics of immunological indicators: increased fugutive therapy performed 6 operations autodermoplastiki, in the result, the skin was fully restored. 3 months after injury, the boy was discharged home in good condition. It should be noted that in later periods of stay in the burn center of sepsis it wasn't found.

2. Patient A. Belyaeva, 4 years, I. B. 184180, arrived in Nizhny Novgorod research Institute of traumatology and orthopedics 28.11.98, about scald I - II - AB extent of the chest, abdomen, left upper extremity on the area of 32% of the body surface. On the background of resuscitation and antibiotic therapy (zinacef 500000 IU 3 times, gentamicin 40 mg 2 times) held immune-corrective therapy: IFN 500000 IU once a day for three days, then cold 1 ml intramuscularly for five days. The girl was removed from a state of severe burn shock and toxemia. Complications of burn disease could be avoided. In 27 days after injury the skin has been fully restored and the girl was discharged from the hospital in satisfactory condition.

Method of prevention of early sepsis in tyazheloobozhzhennykh children increases anti-infective protection of the body by passive and active influence on the immune system. The method allows to reduce the frequency ptx2">

Method of prevention of early sepsis in tyazheloobozhzhennykh children through traditional treatment in the period of burn shock and acute toxemia, characterized in that in the first five days after injury injected in the age dosage intramuscular injection of human recombinant interferon - IFN, and on the sixth day inducer of interferon - cycloferon in the next five days.

 

Same patents:

The invention relates to medicine, in particular to immunology and neurology, and for the treatment of autoimmune diseases

The invention relates to products derived from histamine and, in particular, the condensation products of histamine or methylsiloxanes histamine and amino acids, the method of their preparation and use as active principle in areas such as therapy and cosmetology, as well as the factor (agent), improving the stability of compositions used in therapy, cosmetology, agriculture and food industry (region)

The invention relates to the field of medicine

The invention relates to new 2-methyl-4-amino-6-oxopyrimidine formula I and methods of its production
The invention relates to medicine and can be used in therapy, for immunocorrective

The invention relates to the field of medicine and is suitable for the treatment of seasonal and perennial allergic rhinitis, conjunctivitis, hay fever, urticaria, including chronic idiopathic urticaria, angioedema, psevdoallergicakie reactions caused by the release of histamine, itching dermatoses, allergic reactions to insect bites and itching of various etiology
The invention relates to medicine, namely therapy, and can be used in clinical practice for immune in various diseases

The invention relates to medicine and is a method of prevention and/or treatment of autoimmune diseases, including the introduction of an effective amount of pharmaceutically acceptable salt or complex of magnesium

The invention relates to cyclopentapeptide formula (I):

cyclo (A-B-C-E-F-(D)-Ala)

in which A, B, C, E and F, independently of one another, may be the same or different and represent a residue of a natural amino acid except cysteine (Cys) and tryptophan (Trp), and accordingly can be an alanine (Ala), arginine (Arg), asparagine (Asn), aspartic acid (Asp), glutamine (Gln), glutamic acid (Glu), glycine (Gly), histidine (His), isoleucine (Ile), leucine (Leu), lysine (Lys), methionine (Met), phenylalanine (Phe), Proline (Pro), serine (Ser), tryptophan (Thr), tyrosine (Tyr) or valine (Val), as well as their physiologically compatible salts

The invention relates to medicine, in particular to immunology and neurology, and for the treatment of autoimmune diseases

The invention relates to medicine and for the development of new drugs for the treatment and prevention of viral diseases
The invention relates to medicine, namely to Oncology
The invention relates to pharmacology, specifically to the preparation interferonsource compositions, is able to maintain its biological activity, which can be used as drugs for intranasal use, for example for the preparation of drops in the nose
The invention relates to medicine and can be used for the treatment and prevention of sexually transmitted diseases

The invention relates to medicine and pharmaceutical industry and for the development of new drugs

The invention relates to pharmaceutical industry, production of medicines intended to treat herpes infections of the skin and mucous membranes

The invention relates to medicine, namely to methods of in vitro adoptive immunotherapy, especially in the treatment of patients with viral hepatitis C
The invention relates to food processing and medical industry

The invention relates to certain nucleoside derivative, which was found to possess valuable properties for the treatment of tumors
Up!